Clinical trials: Cancer Refractory
Acute Myeloid Leukemia, Relapse Leukemia
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a open-label, nonramdominzed, single-arm, Phase I/II Study to evaluate safety and tolerability of functionally enhanced CD33 CAR-T cells in subjects with relapsed or refractory acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Relapse Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04835519
- Testing
- chimeric antigen receptor T cell
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Beijing Boren Hospital
Prostate Cancer, Adenocarcinoma of the Prostate
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT00879619
- Testing
- sunitinib malate, docetaxel, prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- John P. Fruehauf
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.
- Trial name
- NCT03778619
- Testing
- Rituximab, Fludarabine, Cyclophosphamide
- Where
- 3 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- GC Cell Corporation
Neoplasms, Lymphoma
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
Background: Cyclophosphamide (CP) is a drug approved by the Food and Drug Administration for the treatment of certain cancers. It works by causing DNA damage, resulting in cell death, including cancer cells.
- Trial name
- NCT01445522
- Testing
- ABT-888, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Generalized Myasthenia Gravis
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.
- Trial name
- NCT01997229
- Testing
- Eculizumab
- Where
- 114 sites in United States, Argentina and 19 more
- Volunteers
- 125 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Myeloma, Plasma Cell Leukemia
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
- Trial name
- NCT05822037
- Testing
- CT0594CP
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose.
- Trial name
- NCT03912831
- Testing
- KITE-439, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- Gilead Sciences
Leukemia, Lymphoma
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy such as sirolimus use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00068302
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Philadelphia
Glioblastoma Multiforme, Glioblastoma
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if appropriate), standard of care chemo-radiation with…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, GBM
- Trial name
- STAR-3 (NCT03149575)
- Testing
- VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- DelMar Pharmaceuticals, Inc.
Leukemia, B-Cell
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic…
- Trial name
- NCT03599375
- Testing
- CD19-targeted CART cells
- Volunteers
- 20 people
- Sponsor
- jiuwei cui
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells and prepares the…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00376519
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Study of bb21217 in Multiple Myeloma
Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT03274219
- Testing
- bb21217
- Where
- 11 sites in United States
- Volunteers
- 72 people
- Sponsor
- 2seventy bio
Colorectal Cancer
Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075595
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Unspecified Adult Solid Tumor, Protocol Specific
Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Mistletoe lectin may slow the growth of cancer cells and be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of mistletoe lectin in treating patients who have refractory…
- Trial name
- NCT00006477
- Testing
- mistletoe extract
- Where
- 2 sites in Germany, Norway
- Volunteers
- 26 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416377
- Testing
- bleomycin sulfate, chlorambucil, dacarbazine
- Volunteers
- 353 people
- Sponsor
- Children's Cancer and Leukaemia Group
Hematologic Malignancies
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies.
- Trial name
- NCT03557619
- Testing
- Venetoclax, ethinyl estradiol/levonorgestrel
- Where
- 4 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- AbbVie
Immunotherapy, Multiple Myeloma
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
The goal of this clinical trial is to study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients with Relapsed/Refractory Multiple Myeloma Primary Endpoints: To…
- Trial name
- NCT05652530
- Testing
- Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shenzhen Pregene Biopharma Co., Ltd.
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Multiple Myleoma, Multiple Myeloma in Relapse
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
The goal of this clinical trial is to evaluate the efficacy of Teclistamab (Te) and autologous lymphocyte infusions (ALI) in relapse refractory multiple myeloma.
- Conditions
- Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
- Trial name
- TALIM (NCT06880601)
- Testing
- Teclistamab
- Volunteers
- 52 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.